A
new study shows that using therapeutic antibodies to block the interleukin-11
protein can reverse idiopathic pulmonary fibrosis.
A
new study has shown that blocking a protein called interleukin-11 (IL-11) using
therapeutic antibodies can reverse idiopathic pulmonary fibrosis (IPF), a type
of lung disease that results in scarring of the lungs, also known as fibrosis.
In
this study, researchers from MRC LMS in collaboration with Duke-NUS Medical
School, National Heart Centre Singapore and National Heart and Lung Institute,
Imperial College London investigated whether therapeutic antibodies could
reverse the process of lung fibrosis, as IL-11 was found to be crucial to the
progression of IPF.
Using
mice, antibodies designed to bind to IL-11 and neutralise its activity were
administered. The treatment not only diminished the damage of the lungs in
these mice, but reversed the fibrosis too, highlighting the potential of IL-11
as a possible target for the treatment of IPF.
“We
found that blocking the IL-11 protein with antibodies could reverse fibrosis in
a mouse model of human lung disease,†said Stuart Cook, Head of the
Cardiovascular Disease Mechanism group at the MRC LMS and senior author of this
study. “This is a remarkable finding as reversing fibrosis is tough to do. We
believe this holds promise for treating fibrotic lung diseases, like IPF, in
patients. We are aiming to test our antibodies in human safety trials by the
end of 2020 and then start clinical trials with patients in 2021.â€
“Idiopathic
respiratory failure is a terrible disease with an untreated life expectancy of
three years,†added Toby Maher, Professor of Interstitial Lung disease and
British Lung Foundation Chair in Respiratory Research at NHLI. “Although we
have treatments to slow disease progression, we desperately need new therapies
to genuinely transform outcomes for people with IPF.
This
exciting research highlights the importance of IL-11 in driving the development
of fibrosis and gives hope for a new treatment approach to halt and maybe even
reverse the devastating lung scarring of IPF.â€
From
source: https://www.drugtargetreview.com/news/49940/target-idiopathic-pulmonary-fibrosis-treatment/
.png)
.jpg)
.gif)
